MINNEAPOLIS, MN, May 9, 2013 /PRNewswire/ - BioAmber Inc. ("BioAmber")
(NYSE: BIOAU), announced today the pricing of its initial public
offering of 8,000,000 units consisting of one share of common stock and
one warrant to purchase half of one share of common stock at $10 per
unit, before underwriting discounts and commissions. Each warrant will
be exercisable at an exercise price of $11.00 per whole share of common
stock. All units are being sold by BioAmber. BioAmber has granted the
underwriters an option for 30 days to purchase up to an additional
1,200,000 units at the initial public offering price, less underwriting
discounts and commissions, to cover over-allotments, if any. The units
are expected to start trading on the New York Stock Exchange ("NYSE")
under the symbol "BIOAU" on May 10, 2013. The common stock and warrants
comprising the units will begin trading separately on NYSE under the
symbols "BIOA" and "BIOAWS", respectively, on the first trading day
following the expiration of the underwriters' 30-day over-allotment
option, at which time trading of the units will be suspended and the
units will be delisted. BioAmber also intends to list its common stock
on the Professional Segment of the regulated market of NYSE Euronext in
Paris under the symbol "BIOA." This offering is expected to close on
May 14, 2013.
Credit Suisse, Barclays and Société Générale are acting as joint
book-running managers for the offering. Pacific Crest Securities is
acting as co-manager for the offering.
A registration statement relating to these securities has been filed
with, and declared effective by, the U.S. Securities and Exchange
Commission on May 9, 2013. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall there
be any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
The offering of these securities is being made only by means of a
prospectus, copies of which may be obtained from Credit Suisse
Securities (USA) LLC by mail at One Madison Avenue, New York, New York
10010, Attention: Prospectus Department, or by calling toll free (800)
221-1037, or by emailing email@example.com.
About BioAmber Inc.
BioAmber is a next generation chemicals company. Its proprietary
technology platform combines industrial biotechnology and chemical
catalysis to convert renewable feedstocks into chemicals including
succinic acid and 1,4-butanediol, which are used in a wide variety of
everyday products such as plastics, food additives and personal care
products. For more information visit the company's web site at: www.bio-amber.com.
This press release contains forward-looking statements, which are
subject to substantial risks, uncertainties and assumptions. You should
not place reliance on these statements. Forward-looking statements
include information concerning the proposed offering. These statements
often include words such as "believe," "expect," "anticipate,"
"intend," "plan," "estimate," "seek," "will," "may" or similar
expressions. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that we
will effect an initial public offering. Accordingly, you should not
place undue reliance on these forward-looking statements. All such
statements speak only as of the date made, and we undertake no
obligation to update or revise publicly any forward-looking statements,
whether as a result of new information, future events or otherwise.
SOURCE BIOAMBER CANADA INC.